- Home
- FSM vs MESO Comparison
FSM vs MESO Comparison
Compare FSM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- MESO
- Stock Information
- Founded
- FSM 1990
- MESO 2004
- Country
- FSM Canada
- MESO Australia
- Employees
- FSM 2490
- MESO N/A
- Industry
- FSM Precious Metals
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSM Basic Materials
- MESO Health Care
- Exchange
- FSM Nasdaq
- MESO Nasdaq
- Market Cap
- FSM 1.4B
- MESO 1.2B
- IPO Year
- FSM N/A
- MESO N/A
- Fundamental
- Price
- FSM $4.59
- MESO $13.17
- Analyst Decision
- FSM Hold
- MESO Strong Buy
- Analyst Count
- FSM 2
- MESO 4
- Target Price
- FSM $5.75
- MESO $11.50
- AVG Volume (30 Days)
- FSM 8.4M
- MESO 238.9K
- Earning Date
- FSM 11-06-2024
- MESO 08-28-2024
- Dividend Yield
- FSM N/A
- MESO N/A
- EPS Growth
- FSM N/A
- MESO N/A
- EPS
- FSM 0.08
- MESO N/A
- Revenue
- FSM $1,025,155,000.00
- MESO $5,902,000.00
- Revenue This Year
- FSM $26.54
- MESO $66.05
- Revenue Next Year
- FSM N/A
- MESO $348.27
- P/E Ratio
- FSM $56.43
- MESO N/A
- Revenue Growth
- FSM 38.19
- MESO N/A
- 52 Week Low
- FSM $2.63
- MESO $1.61
- 52 Week High
- FSM $6.36
- MESO $12.70
- Technical
- Relative Strength Index (RSI)
- FSM 43.14
- MESO 67.62
- Support Level
- FSM $4.51
- MESO $10.30
- Resistance Level
- FSM $5.34
- MESO $11.59
- Average True Range (ATR)
- FSM 0.20
- MESO 0.50
- MACD
- FSM -0.03
- MESO 0.10
- Stochastic Oscillator
- FSM 10.78
- MESO 77.98
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.